Cellular reprogramming: two glaucoma patients show vision improvement in first test

An experimental cellular reprogramming technology has shown the first signs of efficacy in the human body. According to the results of a trial conducted by biotechnology company Life Biosciences, two of three participants diagnosed with glaucoma recorded improvements in specific vision parameters. These are the first known data on the application of a similar method, aimed at restoring cell functions by returning them to a younger state, directly in humans.

Investment interest and scientific context

Technologies that allow slowing down ageing or restoring damaged cells are attracting the attention of leading Silicon Valley investors. Among those financing such biotechnology projects are Jeff Bezos, Peter Thiel, Yuri Milner, and Sam Altman. Until now, cellular reprogramming research has been conducted primarily on animals, making the current trial the first step towards clinical application. However, experts emphasise that the obtained results are preliminary and do not confirm the possibility of fully reversing ageing processes.

Mechanism of action of the ER-100 drug

Life Biosciences is testing the drug ER-100 for the treatment of optic nerve pathologies, specifically glaucoma, which can lead to irreversible vision loss due to damage to retinal cells. The goal of the therapy is to activate genetic mechanisms that allow cells to restore functions characteristic of a younger age.

To achieve this, three reprogramming factors are used: OCT4, SOX2, and KLF4. They influence gene activity, and researchers are checking whether such a change causes the restoration of damaged cells in the visual system. Three patients received an injection of the drug into the eye, after which they took the antibiotic doxycycline daily for eight weeks, which is necessary for activating the reprogramming mechanism.

First data on safety and efficacy

On 8 October 2026, the company published the first reports on the safety of the treatment. According to Life Biosciences, no serious side effects related to the therapy were detected in the three patients, and overall, the treatment was well tolerated.

In addition to safety, improvements in visual field indicators were recorded in two participants. This may indicate the potential benefit of the new approach, although there is currently no evidence that the therapy restored damaged cells or fully returned lost vision.

Ophthalmologist James Tsai, president of the New York Eye and Ear Infirmary of Mount Sinai, who was not involved in the study, assessed the results as interesting but preliminary. In his words, additional data are needed to understand whether the treatment truly restores tissue functions or merely improves existing signals in the visual system.

After analysing the initial results, an independent safety monitoring board allowed the drug dose to be increased threefold for the next group of participants.

Prospects for application against other diseases

If further trials confirm the efficacy and safety of cellular reprogramming, the technology could be adapted for the treatment of other age-related diseases. Representatives of Life Biosciences mention potential directions: arthritis, high blood pressure, fatty liver disease, and neurodegenerative diseases. However, this refers only to possible future applications, not to proven efficacy against these diseases in humans.

Other companies are also working in this field. Altos Labs, supported by Jeff Bezos, is developing cellular rejuvenation research, while startup Retro Biosciences, which received funding from Sam Altman, is also working on longevity technologies.

The main question remains open: whether cellular reprogramming will be able to safely restore human tissue functions in larger-scale studies. The results of the three patients are only the initial stage of testing this hypothesis.